search
Back to results

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

Primary Purpose

Primary Biliary Cholangitis

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
18-22mg/kg/d Ursodeoxycholic
13-15mg/kg/d Ursodeoxycholic
Sponsored by
West China Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Biliary Cholangitis focused on measuring Ursodeoxycholic Acid

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with primary biliary cholangitis
  • Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid

Exclusion Criteria:

  • Autoimmune hepatitis
  • Primary sclerosing cholangitis

Sites / Locations

  • West China HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

18-22mg/kg/d Ursodeoxycholic group

13-15mg/kg/d Ursodeoxycholic group

Arm Description

Outcomes

Primary Outcome Measures

Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC)
Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC) in two arms.

Secondary Outcome Measures

Alkaline phosphatase
(ALP)
Glutamyltransferase
(GGT)
Alanine transaminase
(ALT)
Aspartate transaminase
(AST)
Total bilirubin
(TB)

Full Information

First Posted
November 6, 2017
Last Updated
May 2, 2018
Sponsor
West China Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03345589
Brief Title
A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
Official Title
A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 30, 2018 (Actual)
Primary Completion Date
December 1, 2018 (Anticipated)
Study Completion Date
January 1, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
West China Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the effect of 18-22mg/kg/d Ursodeoxycholic in refractory Primary Biliary Cholangitis

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Biliary Cholangitis
Keywords
Ursodeoxycholic Acid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
18-22mg/kg/d Ursodeoxycholic group
Arm Type
Experimental
Arm Title
13-15mg/kg/d Ursodeoxycholic group
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
18-22mg/kg/d Ursodeoxycholic
Intervention Description
18-22mg/kg/d Ursodeoxycholic
Intervention Type
Drug
Intervention Name(s)
13-15mg/kg/d Ursodeoxycholic
Intervention Description
13-15mg/kg/d Ursodeoxycholic
Primary Outcome Measure Information:
Title
Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC)
Description
Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC) in two arms.
Time Frame
Month 6 during treatment with 13-15mg/kg/d ursodeoxycholic acid or 18-22mg/kg/d ursodeoxycholic acid
Secondary Outcome Measure Information:
Title
Alkaline phosphatase
Description
(ALP)
Time Frame
Week 2 and Month 1, 3, 6,9,12
Title
Glutamyltransferase
Description
(GGT)
Time Frame
Week 2 and Month 1, 3, 6,9,12
Title
Alanine transaminase
Description
(ALT)
Time Frame
Week 2 and Month 1, 3, 6
Title
Aspartate transaminase
Description
(AST)
Time Frame
Week 2 and Month 1, 3, 6, 9,12
Title
Total bilirubin
Description
(TB)
Time Frame
Week 2 and Month 1, 3, 6, 9,12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with primary biliary cholangitis Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid Exclusion Criteria: Autoimmune hepatitis Primary sclerosing cholangitis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ping Ni, MD
Phone
13281091993
Email
545043216@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Li Yang, MD
Organizational Affiliation
West China Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
West China Hospital
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Yang
Phone
+8618980601276
Email
yangli_hx@scu.edu.cn

12. IPD Sharing Statement

Learn more about this trial

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

We'll reach out to this number within 24 hrs